You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (PAH): insights from the randomised controlled griphon trial with selexipag

Alerts

Article menu
Download PDFPDF
Declarations of Interest
S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (PAH): insights from the randomised controlled griphon trial with selexipag
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address